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Notch signaling is essential for hematopoietic stem cell (HSC) formation during embryogenesis, and hitherto
it was also thought to be required for HSCmaintenance. However, in this issue ofCell StemCell, Maillard et al.
(2008) demonstrate rather conclusively that inactivation of the Notch pathway in HSCs does not interfere with
their self-renewal.Maintenance of the blood system, which
contains large numbers of short-lived
cells, requires the constant production
of new cells. Hematopoietic stem cells
(HSCs) that reside in the bone marrow
(BM) ensure that this happens throughout
life. They are rare, usually quiescent cells
that can self-renew and also give rise to
proliferative progenitors that go through
multiple rounds of cell division as they dif-
ferentiate into the various blood lineages.
Maintenance of HSCs in the BM niche is
clearly, therefore, of fundamental impor-
tance. Notch signaling, which is absolutely
required for HSC formation during embry-
onic development (Dzierzak and Speck,
2008), was also thought to play a role in
HSC maintenance in the BM niche (Dun-
can et al. [2005] and references therein).
Maillard and colleagues, however, cast
serious doubt on this latter role (Maillard
et al., 2008).
Notch signaling is accepted as crucial
during splenic marginal B cell develop-
ment and at several stages of T cell devel-
opment, in particular when early lymphoid
progenitors are committing to the T rather
than the B cell lineage. While B cells differ-
entiate in the BM, lymphoid progenitors
that are to become T cells need to leave
the BM and enter the thymus, an organ
that is high in Notch signaling and that
actively supports T cell differentiation
(Han et al., 2002; Tanigaki et al., 2002).
Notch signaling involves a paracrine sig-
nal, whereby transmembrane ligands of
the Delta and Jagged families interact
with one of four Notch receptors on an ad-
jacent cell (Figure 1). Interaction of ligand
and receptor results in two proteolytic
cleavages of the receptor (by ADAM10/
TACE and g-secretase) and the release
of the Notch intracellular domain (NICD)
to the nucleus, where it forms a ternaryprotein complex with the transcription
factor RBPJ (also known as CSL or
Su[H]) and the transcriptional coactivator
MAML. This ternary complex binds regu-
latory elements of Notch target genes
and activates their expression (Bray,
2006).
Gain-of-function experiments were the
first to imply a role for Notch in HSC
self-renewal. These experiments involved
the treatment of HSCs with ligands, over-
expression of constitutively active Notch
alleles or Notch target genes, like Hes1,
in HSCs, or increase of the number of Jag-
ged1-expressing osteoblasts in the BM
environment in vivo: all resulted in an in-
crease in the number of HSCs that could
successfully repopulate the BM of irradi-
ated mice (Duncan et al. [2005] and refer-
ences therein).
Loss-of-Notch-function data were less
clear cut. The conditional knockout of
Notch1 and the combined conditional ab-
lation of Notch1 and Jagged1 in the BM of
adult mice did not reveal any effect on
HSC self-renewal, even under conditions
in which HSCs were forced to proliferate
extensively, as in in vivo challenge assays
with 5-fluorouracil, or to compete with
wild-type HSCs, as in competitive recon-
stitution assays (Mancini et al., 2005).
However, because of potential functional
redundancy with other Notch ligands and
receptors, these experiments did not rule
out a role for Notch signaling in HSC self-
renewal.
The central, obligate role for transcrip-
tion factor RBPJ in canonical Notch
signaling means that interference with its
function should eliminate signaling down-
stream of all Notch ligands and receptors.
Adult mice conditionally ablated for RBPJ
were first analyzed a few years ago by
Tasuku Honjo’s laboratory. They foundCell Stemspecific defects in T cell (Han et al.,
2002) and splenic marginal B cell devel-
opment (Tanigaki et al., 2002). Myeloid
and B cell development in the BM, how-
ever, was normal in the RBPJ-ablated
adults as judged by flow-cytometric anal-
ysis and in vitro colony assays (Han et al.,
2002). This suggested that HSC mainte-
nance was unaffected, at least under
steady-state hematopoiesis. Stringent
assays that forced HSCs into proliferation
or competition with wild-type cells were
not performed. In 2005, Duncan and col-
leagues transduced isolated HSCs with
a retroviral vector in vitro that encoded a
dominant-negative version of the RBPJ
protein (DNRBPJ) that interacts with NICD
but cannot bind DNA. They tested these
cells in competitive long-term reconstitu-
tion assays and found that DNRBPJ-
transduced HSCs displayed a 65%–80%
reduction in repopulating activity in com-
parison to control HSCs (Duncan et al.,
2005), suggesting a role for Notch in HSC
self-renewal under conditions of hemato-
poietic stress. The current paper by Mail-
lard and colleagues challenges this view.
Maillard et al. (2008) used a dominant-
negative version of the coactivator MAML
(DNMAML), which forms a transcription-
ally inactive complex with NICD and
RBPJ in the nucleus and is, therefore,
also meant to inhibit all Notch signaling.
They either transduced a population of
5-fluorouracil-treated BM in vitro with
a DNMAML-expressing retroviral con-
struct or expressed DNMAML condition-
ally from a transgene introduced into the
ROSA26 locus. Using loss of T cell differ-
entiation as a control for Notch signal
depletion, they show that coinjection of
irradiated mice with both types of
DNMAML-expressing hematopoietic BM
cells plus competitors readily gaveCell 2, April 2008 ª2008 Elsevier Inc. 293
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a T cell fate. T cell progenitors need to
leave the BM and seed the thymus, an or-
gan that is high in Notch signaling and that
actively supports T cell differentiation.
Similarly, HSCs isolated from the BM can
respond to active Notch signaling in vitro
(as shown by the gain-of-function studies)
albeit by self-renewing, rather than differ-
entiating into T cells. How LRF and possi-
bly other factors maintain the repression
of the Notch signaling pathway in BM
HSCs and progenitors, and why it is sud-
denly lifted as the cells leave the BM, is
certainly of considerable interest. The fact
that it can be lifted is also of enormous
practical importance as we strive to be
able to expand HSC populations in vivo
and ex vivo for use in stem cell therapies.
Figure 1. The Canonical Notch Pathwaymyeloid reconstitution in the recipient
with the manipulated cells, irrespective
of the phenotype of the transplanted
HSC population (CD45+, B6-Thy1.1 cells,
side population cells, LSK cells, and
CD150+CD48 cells). Furthermore, sec-
ondary competitive transplantation 12
weeks following the primary transplant
and limiting dilution competitive trans-
plantation assays, two very rigorous
assays, revealed no defect in HSC self-
renewal or myeloid differentiation. In addi-
tion, DNMAML-expressing cells behaved
like their wild-type counterparts in the
early stages of hematopoietic recovery
in experiments in which no competitor
cells were coinjected. In line with these
data, cells in which the RBPJ gene had
been conditionally ablated prior to isola-
tion and transplantation contributed nor-
mally to BM HSCs, myeloid, and B cell
lineages in recipients 18 weeks after
transplantation. Altogether, these data
demonstrate rather conclusively that
HSC function, even under conditions of
hematopoietic stress, is not affected by
the inability to transduce Notch signals
(Maillard et al., 2008).
Why expression of a DNRBPJ protein in
BM HSCs leads to a defect in self-renewal
whereas conditional ablation of RBPJ and
misexpression of a DNMAML does not294 Cell Stem Cell 2, April 2008 ª2008 Elsevis currently unclear. It is possible that
DNRBPJ not only abrogates expression
of target genes of the canonical Notch
signaling pathway but also has a negative
impact on other cellular processes. Fur-
ther work on the DNRBPJ-expressing
cells may shed light on this mystery.
Notch ligands are expressed in the BM
environment, and Notch-expressing BM
mesenchymal stem cells require Notch
signaling not just to self-renew but also
to drive the proliferation of osteoblast pro-
genitors that are derived from them (Engin
et al., 2008; Hilton et al., 2008). Despite
the presence of ligands in the BM and
the expression of receptors by the BM
blood progenitors, Maillard et al. (2008)
find that expression of typical Notch tar-
get genes is low in these blood cells and
that some target genes, like Hes1, are ex-
pressed in a Notch-independent fashion.
Knockout mice that carry a targeted dele-
tion of the widely expressed lymphoma-
related factor (LRF, also known as
Pokemon) express Notch target genes in
BM progenitors and undergo abnormal T
cell instead of B cell differentiation in the
BM (Maeda et al., 2007). These results
suggest that LRF normally downregulates
Notch signals in hematopoietic progeni-
tors, thus making them insensitive to the
presence of Notch ligands in the BM envi-ier Inc.REFERENCES
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